Preserving the future of medicine: standardizing leukapheresis materials with cryopreservation for scalable cell therapies
Uncover insights to tackle variability, optimize processes, and scale cell therapies globally.
The advancement of cell therapies has brought incredible opportunities to improve patient outcomes, but the complexity of manufacturing and delivering these therapies demands innovative approaches. Variability in leukapheresis materials and the logistical challenges of cryopreservation remain critical hurdles for many therapeutic developers. In this roundtable discussion, industry experts explore strategies to drive standardization and efficiency, sharing their expertise to help overcome these challenges.
From the benefits of cryopreservation to managing multi-site qualification and optimizing supply chains, this webinar provides a comprehensive overview of best practices for scaling cell therapies. By addressing these critical factors, organizations can better position themselves to navigate the path from clinical to commercial success while ensuring quality and patient safety at every step.
IntegriCell™ cryopreservation services from Cryoport Systems optimize leukapheresis-derived cell therapies by enhancing the safety, quality, and viability of manufacture-ready cryopreserved leukopaks. Our state-of-the-art cryopreservation process, integrated with our end-to-end global temperature-controlled supply chain platform, provides unmatched reliability, efficiency, and scope.